コンテンツにスキップ

Pharmacovigilance: A Practical Approach, 1st Edition

著者 :
Edited by Thao Doan, MD, Linda Scarazzini, MD, Cheryl Renz, Fabio Lievano, MD, PhD H.C. and Mondira Bhattacharya, MD
Written by experts in the field of pharmacovigilance and patient safety, this concise resource provides a succinct, easy-to-digest overview of an increasingly critical area of medical safety. Drs. Thao Doan, Fabio Lievano, Mondira Bhattacharya, and L ...view more

Written by experts in the field of pharmacovigilance and patient safety, this concise resource provides a succinct, easy-to-digest overview of an increasingly critical area of medical safety. Drs. Thao Doan, Fabio Lievano, Mondira Bhattacharya, and Linda Scarazzini provide essential information for health care professionals, clinical researchers, and regulators who need a comprehensive, up-to-date source of information on the principles and practice of pharmacovigilance.

ISBNコード :
9780323581172
出版日 :
31-07-2018
カートに入れる

!洋書籍は不課税のため消費税不適用、電子書籍は消費税がご注文決済前に表示・適用されます!

!消費税はご注文決済前に表示・適用されます!

Written by experts in the field of pharmacovigilance and patient safety, this concise resource provides a succinct, easy-to-digest overview of an increasingly critical area of medical safety. Drs. Thao Doan, Fabio Lievano, Mondira Bhattacharya, and Linda Scarazzini provide essential information for health care professionals, clinical researchers, and regulators who need a comprehensive, up-to-date source of information on the principles and practice of pharmacovigilance.


特長
  • Covers the evolving regulatory landscape, as well as current and future use of digital technologies.
  • Uses case studies to ensure content is relevant to everyday practice.
  • Discusses behavioral science and patient perspectives, risk communication, and new frontiers in pharmacovigilance.
  • Consolidates today’s available information on this timely topic into one convenient resource.

著者情報
Edited by Thao Doan, MD, Group Medical Director, Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, AbbVie, North Chicago, IL, United States; Adjunct Faculty, Loyola University Stritch School of Medicine, Maywood, IL, United States; Adjunct Faculty, Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Linda Scarazzini, MD, Senior Vice President, Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, Chief Safety Officer, AbbVie, North Chicago, IL, USA; Cheryl Renz, Senior Medical Director, Safety Science, Pharmacovigilance and Patient Safety, AbbVie, North Chicago, Illinois, United States; Fabio Lievano, MD, PhD H.C., Vice President, Patient Safety, Scientific Collaborations, and New Business Advancement, Pharmacovigilance and Patient Safety, Epidemiology and, R&D Quality Assurance, AbbVie, North Chicago, IL, United States; Adjunct Faculty, Loyola University Stritch School of Medicine, Maywood, IL, United States; Adjunct Faculty, Northwestern University Feinberg School of Medicine, Chicago, IL, USA and Mondira Bhattacharya, MD, Head, Benefit-Risk Management, Innovative Platforms Initiative & Epidemiology, Pharmacovigilance and Patient Safety, AbbVie Inc., Chicago. IL
詳細情報
ISBN Number 9780323581172
Description Author List Edited by Thao Doan, MD, Group Medical Director, Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, AbbVie, North Chicago, IL, United States; Adjunct Faculty, Loyola University Stritch School of Medicine, Maywood, IL, United States; Adjunct Faculty, Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Linda Scarazzini, MD, Senior Vice President, Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, Chief Safety Officer, AbbVie, North Chicago, IL, USA; Cheryl Renz, Senior Medical Director, Safety Science, Pharmacovigilance and Patient Safety, AbbVie, North Chicago, Illinois, United States; Fabio Lievano, MD, PhD H.C., Vice President, Patient Safety, Scientific Collaborations, and New Business Advancement, Pharmacovigilance and Patient Safety, Epidemiology and, R&D Quality Assurance, AbbVie, North Chicago, IL, United States; Adjunct Faculty, Loyola University Stritch School of Medicine, Maywood, IL, United States; Adjunct Faculty, Northwestern University Feinberg School of Medicine, Chicago, IL, USA and Mondira Bhattacharya, MD, Head, Benefit-Risk Management, Innovative Platforms Initiative & Epidemiology, Pharmacovigilance and Patient Safety, AbbVie Inc., Chicago. IL
Copyright Year 2019
Edition Number 1
Format E-Book
Trim Other
Imprint Elsevier
Page Count 0
Publication Date 31 Jul 2018
Stock Status IN STOCK

Introduction

Section I. The Regulatory Enviroment

1. Does Regulation Drive Science or Does Science Drive Regulation?

Section II. Data and Real World Evidence

2. Role of Epidemiology in Pharmaceutical Industry

3. Real World Epidemiologic Studies and Patient Registries

Section III. Benefit-Risk in the Drug Development Life Cycle

4. Signal Management and Methods of Signal Detection

5. Causality Assessment and Examples of Adverse Drug Reactions (Drug Induced Liver Injury, Skin, Major Adverse Cardiac Events and Renal)

6. Product Safety Monitoring in Clinical Trials

7. Benefit-Risk Assessments

8. Communicating benefit risk

9. Pharmacovigilance and Medical Devices

10. Vaccine Safety Surveillance

11. Pharmacovigilance in Special Populations (Pediatrics and Elderly)

12. Pharmacovigilance in Pregnancy

Section IV. The Role of the Digital Revolution

13. Impact and Implications of Technology on Pharmacovigilance

Section V. The Next Frontier

14. The Future of Pharmacovigilance

あなたのレビューを投稿する
登録ユーザーのみがレビューを書くことができます。 ログインするか、アカウントを作成してください